Prolonged release formulation of liraglutide (Nanexa)

N/A

Report date: 2024/06/24 11:33:19

Base Information

Drug NameProlonged release formulation of liraglutide (Nanexa)
Drug Alias NameLong acting Liraglutide (Nanexa)NEX-22ANEX-22
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNanexa AB
China Registration ClassN/A

Develop Information

Active CompaniesNanexa AB
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A